skip to content

Multiscale within-host modelling of SARS-CoV-2 infection reveals benefits and risks of early Remdesivir treatment

Presented by: 
Farzad Fatehi Chenar
Tuesday 7th July 2020 - 15:00 to 15:30
INI Seminar Room 2
The SARS-CoV-2 outbreak has infected over ten million, and killed over 500,000, individuals worldwide, making the development of antiviral treatments against this virus a priority. Recent studies have identified Remdesivir as an effective antiviral treatment option for COVID-19. I will present a new stochastic agent based model for the intracellular dynamics of a SARS-CoV-2 infection that includes details on all essential steps of a viral life cycle, from viral entry to virion release. Using this model, I evaluate the effect of Remdesivir on the production of new virions. In a next step, I propose an intercellular model to study the viral dynamics within the body of an infected patient. The intercellular model is fitted to data recording the progress of viral load in 12 patients with COVID-19, showing how differing strengths of immune response can explain the variety of infection spans seen in patients. Coupling the intra- and intercellular models allows for a comparative analysis of Remdesivir therapy for patients with different types of immune response.

University of Cambridge Research Councils UK
    Clay Mathematics Institute London Mathematical Society NM Rothschild and Sons